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Abstract
Francisella tularensis is a category A select agent based on its infectivity and virulence but
disease mechanisms in Francisella tularensis infection remain poorly understood. Murine
pulmonary models of infection were therefore employed to assess and compare dissemination and
pathology and to elucidate the host immune response to infection with the highly virulent Type A
F. tularensis strain Schu4 versus the less virulent Type B live vaccine strain (LVS). We found that
dissemination and pathology in the spleen was significantly greater in mice infected with F.
tularensis Schu4 compared to mice infected with F. tularensis LVS. Using gene expression
profiling to compare the response to infection with the two F. tularensis strains, we found that
there were significant differences in the expression of genes involved in the apoptosis pathway,
antigen processing and presentation pathways, and inflammatory response pathways in mice
infected with Schu4 when compared to LVS. These transcriptional differences coincided with
marked differences in dissemination and severity of organ lesions in mice infected with the Schu4
and LVS strains. Therefore, these findings indicate that altered apoptosis, antigen presentation and
production of inflammatory mediators explain the differences in pathogenicity of F. tularensis
Schu4 and LVS.
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1. Introduction
Francisella tularensis causes a fatal disseminated infection upon inhalation. While the
majority of clinically diagnosed disease is due to arthropod bites or handling of infectious
material, interest in Francisella pneumonic infection has been renewed due to the fear of
bioterrorism and its history of weaponization [1,2]. Pneumonic tularemia is the most severe
form of the disease and can result in mortality if treatment is not initiated early in infection.
In addition, relapse after the completion of treatment is a primary concern with bacteria of
such high virulence [3–5]. Despite a substantial revival in F. tularensis research, the
mechanisms of pathogenesis and dissemination remain to be elucidated. Greater knowledge
of the host-pathogen interaction will aid in development of protective vaccines and effective
chemotherapeutics.
F. tularensis Schu4 and LVS were selected for these studies because of the known
difference in virulence associated with these strains, which provides a model with which to
assess differences in host interaction and response genes [6–10]. Schu4 and LVS belong to
the F. tularensis subspecies tularensis and holarctica respectively [11,12]. Subspecies
tularensis, referred to as type A, represents the most virulent of the Francisella subgroups
whereas subspecies holarctica, referred to as type B, tends to be less deadly in humans [1].
LVS is the vaccine strain of F. tularensis, which was derived from a less virulent type B
isolate [12]. While F. tularensis LVS retains its virulence in mice, lethal infection requires
challenge with greater than103 CFU by the pulmonary route, whereas challenge with Schu4
causes a consistent lethal infection with fewer than 102 CFU [9,7]. In addition time-to-death
in the murine pulmonary infection model differs, with Schu4 infection typically resulting in
death by 120 hours post infection, while LVS infected mice survive up to 14 days following
infection [13,7,9,14]
To understand how infection with virulent F. tularensis leads to a rapidly disseminating and
lethal infection, studies have been performed in a variety of different infection models. In
vitro studies aimed at characterizing the transcriptional response to F. tularensis using
multiple cell types have revealed some insights into the host pathogen interaction [15–18].
Andersson et al. examined the whole lung transcriptional response to infection with type A
Francisella isolate FSC033, and found limited host gene expression in the first 4 days of
infection, suggesting a subversion of host recognition and delayed immune responses until
immediately before death [15]. Schu4 mutant strains have also been used to assess host-
pathogen interactions [19–22]. The mutant bacterial strains are generally less virulent in
mouse models of infection. However, studies with mutant strains of F. tularensis have not
yet been employed to study the overall host response to infection. Rather, they have been
more instrumental in assessing the role of specific bacterial components in establishing
infection leading to pathology in the lung.
Monitoring bacterial growth and dissemination along with pathology and in vivo
transcriptional profiling of the host response to infection has provided important advances in
understanding the host-pathogen interaction for organisms such as Listeria [23],
Mycobacteria [24], and Yersinia [25]. Therefore, we believe this is also an appropriate
technique for assessing the host response to infection in the F. tularensis mouse model of
infection. The present work is to our knowledge the first comprehensive comparative study
to define the host transcriptional response to F. tularensis infection following dissemination
from the lungs to secondary sites of infection. In the present study, bacterial burden was
monitored, pathology was assessed, and global gene expression was examined throughout
the course of infection with F. tularensis, comparing infection with the Schu4 and LVS
strains in a murine model. Here we report significant differences in pathology and regulation
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of expression of host immune response genes following infection with the Schu4 and LVS
strains of F. tularensis.
2. Materials and Methods
2.1 Bacterial strains
F. tularensis Schu4 and LVS were provided by Dr. J. Peterson (Centers for Disease Control,
Fort Collins, CO). Schu4 and LVS were cultured in modified Mueller-Hinton broth at 37 °C
with constant shaking overnight, supplemented with 10% glycerol and aliquoted into 1 ml
samples, frozen at −80 °C, and thawed just before use. Frozen stocks were titered by
enumerating viable bacteria from serial dilutions plated on modified Mueller-Hinton agar as
previously described [26]. The number of viable bacteria in frozen stock vials varied <5%
over a 10-month period.
2.2 Mice
Six week-old female C57BL/6 mice were purchased from Jackson Laboratories, Bar Harbor,
Maine. All mice were housed in sterile micro-isolator cages in the laboratory animal
resources facility or in the Rocky Mountain Regional Biocontainment Laboratory BSL-3
facility at Colorado State University (Fort Collins, CO) and provided water and food ad
libitum. All research involving animals was conducted in accordance with the Animal Care
and Use Committee approved animal guidelines and protocols.
2.2.1 Murine models of infection—Mice were infected with either F. tularensis Schu4
or F. tularensis LVS via intranasal (i.n.) or aerosol routes as described previously [27,28]
depending on the objective of the study. For pathology, qRT-PCR, and bacterial burden
studies mice were infected via intranasal route. Mice were anesthetized with ketamine-
xylazine and 10 μL inocula was administered to each of the nares in sequential droplets
allowing mice to inhale the fluid (20 μL total). Infected mice were monitored for morbidity
twice daily and were euthanized at pre-determined endpoints. For global transcriptional
profiling, mice were exposed to F. tularensis Schu4 or F. tularensis LVS by exposure in a
Glas-Col Inhalation Exposure System (Glas-Col, Inc, Terre Haute, IN). Exposure was
conducted by aerosolizing approximately 3.5 × 107 CFU in a volume of 5 cubic feet over a
period of 30 min, followed by a 20 minute period of cloud decay.
2.3. Histopathology
C57BL/6 mice (n = 4 per group per time point) were infected i.n. with the F. tularensis
Schu4 strain (102 CFU) or the F. tularensis LVS strain (104 CFU) and then sacrificed at 48
and 120 hours after exposure. Lung and spleen tissues were removed, divided and placed in
10% neutral buffered formalin for histopathology or in sterile PBS for bacterial
quantification. Organs for histopathological examination were fixed, imbedded in paraffin,
sectioned, and stained with hematoxylin and eosin.
2.4 Bacterial quantification
Samples of lung and spleen tissues were homogenized in 5 mL sterile PBS using a
stomacher (Teledyne Tekmar, Mason, OH). Bacterial CFU per mL of organ homogenate
were determined by plating serial 10-fold dilutions of organ homogenates on modified
Mueller-Hinton agar and incubating at 37 °C for 72 hours. RT-PCR was carried out on RNA
samples from the lungs using a 16s primer set and approach adapted from Cole et al. [29].
Relative detection of 16s molecules was determined using the ΔCT method.
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2.5 RNA Isolation and amplification
RNA was stabilized and recovered from mouse organs by the addition of TRIzol reagent and
organic partitioning. Total RNA was extracted from the TRIzol by the addition of
chloroform (1:1) to achieve a bi-phase separation, then precipitated by the addition of
isopropanol and subjected to Dnase treatment, and purified using a Qiagen RNeasy kit
(Valencia, CA). Messenger RNA was converted to cDNA using poly(T) primers and
amplified in the presence of modified dUTPs using the AminoAllyl Message Amplification
Kit (Ambion, Foster City, CA). Indirect labeling of cDNA for hybridization was conducted
by conjugating Cy3 dye with modified dUTPs in a subsequent reaction.
2.6 Microarray Scanning and Analysis
Full mouse genome version 4.0.3 (Operon Biotechnology, Huntsville, AL) cDNA spotted
microarrays were obtained from the Genomics Proteomics Core of the Rocky Mountain
Regional Center of Excellence (http://www.rmrce.colostate.edu/). The 70mer
oligonucleotide cDNAs were printed on poly-amine coated slides (ArrayIt Corporation,
Sunnyvale, CA) and post-processed by UV cross linking and blocking with 10% BSA and
3X SSC at 42 °C. Dye coupled cDNA, was combined with yeast tRNA (10 mg/mL), and
hybridization buffer (formamide, 20XSSC and 10%SDS) and heated. Single channel (Cy3)
hybridization was carried out in triplicate for each sample. Slides were scanned using the
Genepix 4000B (Molecular Devices, Sunnyvale, CA) fluorescent scanner and analyzed
using Genepix Pro 6.0 software. Background fluorescence was corrected for by subtracting
background from foreground intensity values. Technical replicates were averaged before
normalizing to the global mean intensity values from the entire data set. Log transformation,
t-test, ANOVA, principal component analysis and Benjamini and Hochberg false discovery
correction were applied to the data using the Genesifter software (Geospiza, Seattle, WA).
Genes considered to be differentially expressed were induced or repressed by 1.5 fold or
higher and had a p-value of 0.01 or lower. Clustering was conducted using Cluster software
[30] (http://rana.lbl.gov/eisen/?page_id=42). Functional enrichment analysis was conducted
using the DAVID Bioinformatics Database [31,32] (http://david.abcc.ncifcrf.gov/).
Response to each strain was then compared to controls to examine changes in expression of
genes during the progression of the infections. The complete dataset is available through the
Gene Expression Omnibus (GEO) database using accession # GSE22203.
2.7 qRT-PCR
Quantitative real time PCR was used to assess bacterial burden in infected tissues, validate
microarray data, and monitor molecular markers of disease. Briefly, cDNA synthesis from
total RNA was carried out using First Strand cDNA Synthesis Kit (Invitrogen, Carlsbad,
CA). Briefly, 1 mg of total RNA was combined with random hexamer and oligo (dT)
primers and heated in 10ml total volume for 5 minutes. 10 μL of buffered enzyme mix (2 μL
10X buffer, 4 μL MgCl2 (6 mM), 2 μL DTT (0.1 M), 1 μL RNAse out, and 1 μL
Superscripttm) was added and incubated at 25 °C for 10 minutes, 50 °C for 50 minutes, and
85 °C for 5 minutes. Platinum SYBR Green qPCR Supermix-UDG (Invitrogen, Carlsbad,
CA) was combined with gene specific primers (5nmol) and 50ng of template (cDNA) and
run in triplicate on an IQ5 thermocycler (Bio-Rad, Hercules, CA). The transcripts encoding
18S rRNA, GapDH, and β-actin were used to monitor consistency in biological replicates.
Other genes described in the text where employed to confirm the expression trends
identified by microarray analysis. Resulting data from each condition was compared to
controls in an independent fashion using the ΔCT method.
Kingry et al. Page 4
Microbes Infect. Author manuscript; available in PMC 2012 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
3. Results
3.1 Dissemination, and lung and spleen pathology following infection
To assess possible differences in dissemination to the spleen, and pathology between F.
tularensis strains Schu4 and LVS, mice were infected by the intranasal route. The intranasal
route of infection was chosen for the dissemination and pathology studies in order to
facilitate equalizing the bacterial burden in the lungs at the 48h time point. To accomplish
this, it was necessary to accurately administer higher challenge doses of F. tularensis LVS
than for F. tularensis Schu4. In addition, we also employed a higher intranasal challenge
dose of F. tularensis LVS because there was minimal lung pathology noted when mice were
subjected to low-dose aerosol challenge with F. tularensis LVS (data not shown).
Accordingly, by assuring that mice had equivalent bacterial burdens at the appropriate time
points after infection, we were able to directly compare the efficiency of bacterial
dissemination from the lungs and the associated organ pathology.
Bacterial load in lung and spleen tissue at different times of infection was determined by
molecular detection of F tularensis 16S RNA and confirmed by direct plating of organ
homogenates for F. tularensis colony detection. At 24 hours after inoculation, the bacterial
load of Schu4 and LVS in the lungs was similar based on 16S RNA (Fig. 1A) and colony
counting. For example, the lungs contained 4.4 ± 0.30 Log10 CFU Schu4 and 4.9 ± 0.30
Log10 CFU LVS at 24 hours of infection. In contrast, by 120 hours of infection, there was a
significantly higher bacterial load in the lungs of mice infected with Schu4 (8.6 ± 0.09
Log10 CFU Schu4 versus 7.3 ± 0.49 Log10 CFU LVS). Although the bacterial load in the
spleen was relatively low, Schu4 was detectable by 16S RNA as early as 24 hours after
infection, while LVS was not detectable by 16S RNA until 48 hours after infection (Fig.
1B). At 120 hours after infection, Schu4 and LVS were detected in the spleen, though the
splenic bacterial burden was significantly (p<0.001) higher in Schu4 infected mice (8.3 ±
0.26 Log10 CFU Schu4 versus 5.8 ± 0.28 Log10 CFU LVS). Overall, Schu4 demonstrated
greater growth in the lungs, quicker dissemination to the spleen, and more rapid growth in
the spleen compared to LVS. This observation is consistent with the known, more rapid
disease progression and virulence of Schu4 compared to LVS [9,7]. Further these data
suggest that rapidity of dissemination to secondary sites is related to the extent of infection
in the lungs.
In lung tissues collected from mice 48 hours after infection with either Schu4 or LVS, there
was mild to moderate perivascular edema, extravasation of erythrocytes and mild leukocyte
margination in pulmonary vessels (Fig. 2A). In addition, there were perivascular interstitial
accumulations of granulocytes, monocytes and macrophages, which were accompanied by
minimal cell degeneration and necrosis. At 120 hours of infection both F. tularensis Schu4
and LVS infected lungs had pathologic changes consisting of multifocal interstitial edema
and increased infiltration of granulocytes and monocytes and macrophages along with intra-
alveolar accumulations of macrophages (Fig. 2B). While infection with both Schu4 and LVS
induced lung pathology, the lungs from F. tularensis LVS-infected mice lacked abscesses
and had less well-defined lesions with minimal necrosis compared to lungs from F.
tularensis Schu4-infected mice, which were characterized by prominent abscesses and well-
defined lesions with an increased amount of necrosis (Figs. 2B, C).
Spleen tissues from F. tularensis Schu4 and LVS infected mice collected 48 hours after
infection were histologically unremarkable and indistinguishable from spleens of uninfected
animals (Figs. 2A, B). By 120 hours after infection (Fig. 2C), spleens from F. tularensis
LVS infected mice had mild lymphocyte depletion of the white pulp and multifocal
accumulations of granulocytes and macrophages in the red pulp, with little evidence of
necrosis. In contrast, spleens from F. tularensis Schu4-infected mice had almost complete
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destruction of parenchymal structures due to diffuse severe necrosis, fibrin-deposition and
massive lymphocyte depletion. The marked increase in spleen pathology in F. tularensis
Schu4-infected mice was the most notable histological difference between infections caused
by the two strains of bacteria.
3.2 Common trends in the host response to F. tularensis Schu4 and LVS infection
Whole genome transcriptional profiling of lungs and spleen tissues collected at 12, 24, 48,
and 120 hours of infection from mice infected via aerosol with Schu4 or LVS was conducted
to investigate the global host response to infection with each bacterium. Low dose aerosol
inoculation was used for the transcriptional studies in mice because this route is believed to
more closely approximate human infection by inhalation of F. tularensis than other routes of
infection. Genes that were considered to be differentially regulated had a variance <0.01
(ANOVA) and were up or down-regulated > 1.5 fold compared to uninfected mice. The
complete dataset is available through the Gene Expression Omnibus (GEO) Accession #
GSE22203.
The total number of differentially expressed genes in the lung and spleen paralleled the
bacterial burden. Infection with Schu4 resulted in differential regulation of 3,958 and 5,442
genes in lungs and spleen respectively, compared to uninfected mice. A similar range of
differences in global responses was also observed in LVS infected mice, which resulted in
2,230 differentially regulated genes in the lungs and 9,388 differentially modulated open
reading frames in the spleen. Global gene expression response data from all time points of
infection with LVS and Schu4 were interrogated to identify ontologies and pathways that
were over-represented in the host response to infection (Fig. 3A and 3B). Genes associated
with inflammation, host-pathogen interactions, cellular activation/differentiation, host
antimicrobial activity, and leukocyte receptor signaling constituted the majority of the host
response to infection with both strains of F. tularensis (Table 1).
Infection with either strain resulted in the down-regulation of Il-1β expression immediately
following infection in the lungs. Il-1β is a potent inflammatory cytokine and its suppression
may be a key mechanism in Francisella infection. Upregrulation of Tgfβ1 and Ptger1
expression was noted 48 hours post infection in Schu4 infected mice, and expression of
these immunosuppressive cytokines may be key to the rapid dissemination of Schu4. For
example, Tgfβ1 and Ptger1 have both been shown to play a role in the suppression of host
defenses in the lungs of LVS infected mice and in human dendritic cells infected with Schu4
[33,34],. There was also altered expression of several MHC genes and the killer cell lectin-
like receptor family genes, including (Ly49/Klra) and H2-Ab1, H2-Bl, H2-M10.2, H2-M3,
H2-Q8. The Ly49/Kllra killer cell lectin-like receptors have been shown to be vital for
recognition and activation/inhibition of natural killer cells [35,36]. The fact that Schu4 and
LVS infection both decreased the expression of these receptors adds further evidence to the
notion that F. tularensis evades the host innate immune response by suppressing key
mediators of this response.
3.3 Differences in host response to infection with Schu4 and LVS
Although the overall host response to infection with F. tularensis Schu4 and LVS is similar,
unique host transcriptional responses to infection with Schu4 or infection with LVS
infection were identified. Further inspection of the transcriptional response to Schu4
revealed notable differences in the transcription of immunologically important genes relative
to their expression in LVS-infected mice. These differentially expressed genes included
genes encoding components involved in apoptosis, antimicrobial activity, inflammatory
response, cellular activation and differentiation, leukocyte receptors, and cell signaling
(Table 2).
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Genes associated with apoptosis and antimicrobial activity had different expression patterns
in Schu4 as compared to LVS and uninfected mice. For example, expression of the pro-
apoptotic genes Bad, Bnip2, Bnip3l, Pdcd2, Pdcd4 and Pdcd6, and the anti-apoptotic genes
Bcl2 was repressed in Schu4 infected lungs compared to LVS-infected lungs. Similarly, in
the spleen there was also repression of apitd1, Bclaf1 and Casp6 expression. Inhibition of
apoptosis has been shown to be an important mechanism for replication and survival during
infection of other bacteria such as C. burnetii [37–39].
The antimicrobial activity response in the lungs of F. tularensis Schu4 infected mice was
dominated by altered expression of Adam2 and Adam9, cathepsin D, L, S and Z,
thrombomodulin, thrombospondin 1 and 2, and Timp3. In the spleen, Adam15, Defb1, and
Defb21 showed increased expression, while cathepsin B, D and E had significantly reduced
expression. The transcriptional response of these genes indicated a reduction in tissue
remodeling and breakdown, intracellular protein metabolism, and breakdown of antigenic
proteins for MHC-II presentation. Defensins are intrinsically antimicrobial but the isoforms
induced during infection have been shown to have little effect on Francisella using human
alveolar cells in vitro [40].
The transcription of CD4, CD52, CD74 (Ii, Invariant chain), and B lymphocyte markers
CD37 and CD79B (Igβ) involved in cellular activation and differentiation were uniquely
upregulated in Schu4 infection. The increased expression of these particular components
involved in MHC-II antigen presentation is consistent with augmented cell-mediated
immunity. As antigen presentation is a tightly regulated process [41], these data in addition
to the cathepsin data above may implicate F. tularensis induced alterations in processing and
presentation of antigens during infection with F. tularensis Schu4.
There were also important differences in the molecular mediators of the inflammatory
response in mice infected with Schu4 compared to LVS infected mice. Expression of the
genes for IL-13, IL-13Ra2, CCL2, CCL6, CCL22, and CXCL10 were only induced in the
lungs of Schu4 infected mice. Upregulated expression of IL-13 is important because of its
role as a Th2 related cytokine, which can be associated with downregulation of Th1
immunity. Upregulation of the chemokine genes suggests that Schu4 infection may lead to
increased recruitment of monocytes. A similar trend of altered expression of cytokines and
chemokines, specifically IL-13, CCL3, CCR3, CCR5, interferon activated genes,
prostaglandin D2 synthase 2, prostacyclin I2, prostaglandin reductase 2, and several Ly6-
family genes was observed in the spleen of Schu4 infected mice, albeit later time points in
infection. Interferon activated gene families as well as prostaglandin signaling has been
shown to be involved in the response to virulent Francisella [13,42]. We found similar
involvement of these pathways in response to Schu4 infection in the mouse spleen.
Interestingly, the expression of the T-helper 2 type interleukin IL-13, anti-inflammatory
cytokines IL-10 and TGFβ, and the down regulation of the proinflammatory cytokines IL-18
and interferon alpha suggest a disruption in the activation of the protective defenses in
Schu4 infection compared to LVS infection.
3.4 Validation of transcriptional trends by qRT-PCR
To confirm the transcriptional response of select immunological genes during F. tularensis
infection, quantitative real-time PCR (qRT) was performed on lung and spleen tissue from
independent infections (Table 3). Analysis revealed that the trends identified by global
microarray analysis were 85% and 62% concordant with qRT data in the lung and spleen,
respectively. The lower concordance noted in the spleen is attributed to temporal differences
in dissemination. The expression of the 12 key pro-inflammatory and anti-inflammatory
markers in the lung and spleen was limited in the initial 24 hours of infection. However, 48
hours post infection with LVS shows activation of cytokine and chemokine expression not
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seen until 120 hours post infection with Schu4. The genes significantly up-regulated as
determined by qRT in the lungs during Schu4 infection included the pro-inflammatory
chemokines CCL4, CXCL1 and CXCL10; the pro-inflammatory cytokines IL-6 and IL-12a;
the gene for inducible nitric oxide, Nos2; and the gene for a type I interferon, IFN-β. A
similar trend in the differential expression of these genes was observed in the spleen of
Schu4-infected mice at 120 hours. This trend in transcriptional activity indicates a delayed
and reduced host response to infection with Schu4 and is consistent with a lack of host
recognition or active mechanism of host-response suppression by the Schu4, consistent with
previous reports [43,26,34].
4. Discussion
A critical question in understanding F. tularensis pathobiology is to determine which critical
host responses are altered during the first 4–5 days following infection. Whole genome
microarrays are an established post-genomic approach that allow the assessment of global
host responses in an unbiased fashion. In the present study, we coupled whole genome
microarray analysis with analysis of tissue pathology and organ bacterial burden to gain a
more complete understanding of disease progression and host response to infection with a
fully virulent and a less virulent strain of F. tularensis. By means of this combined approx
we were able to identify important host response differences to infection with the two strains
of F. tularensis.
Quantification of bacterial burden in the lungs revealed that Schu4 had increased growth
compared to LVS, such that by 120 hours the bacterial load of Schu4 in the lungs
significantly exceeded that of mice infected with the LVS strain. In addition, F. tularensis
Schu4 demonstrated increased dissemination to the spleen, as indicated by detection within
48 hours of infection and significantly increased bacterial burden in the spleen at later time
points following infection. Tissue damage was markedly more severe in the spleen
following infection with Schu4, particularly at later time points of infection. Notably, both
Schu4 and LVS established similar levels of infection in the lung, but eventually the Schu4
infection progressed to more severe pulmonary pathology, presumably due to more rapid
replication and avoidance of host immune responses. Efficient dissemination appears to be
an important distinction and hallmark of infection with highly virulent strains of F.
tularensis [14,44,45]. Importantly, the correlation between controlled dissemination and
survival has been observed in drug development studies that indicate that drug efficacy is
related to control of dissemination to secondary organs such as the spleen [45].
Rapid dissemination is an important determinant of disease outcome and likely relies on the
initial recognition and control of pathogen replication at the site of infection. A study
conducted by Chiavolini et. al showed the importance of the initial inflammatory response
in determining survival following F. tularensis infection. For example, survival was
predicted by the induction of several inflammatory genes before day 7 of infection with LVS
in mice [44]. Since replication of Schu4 was actually higher in the spleens of infected mice
than replication of LVS, it is likely that the decrease in cytokine gene expression in the lungs
of Schu4 infected mice reflects either failure to activate immune responses, or active
immune suppression.
The results of the global analyses of the host response to infection with Francisella Schu4 or
LVS strains indicate highly virulent strains are capable of subverting the host innate immune
response and cell mediated immunity. In the present study, these altered responses included
apoptosis, antigen processing and presentation, the inflammatory response, and leukocyte
receptor signaling. The down regulation of multiple host defense mechanisms by F.
tularensis is consistent with results reported in previous studies [15,13,18,17,16][34,43,26].
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In addition, the transcriptional response to Schu4 and F. tularensis subspecies novicida in
human monocytes found that reported that there was less inflammatory gene activation by
Schu4 as compared to the less virulent F. novicida strain [17].
In addition, we found F. tularensis Schu4 versus LVS induced changes in novel gene
subsets, particularly IL-13, cathepsins, and most strikingly, the killer cell lectin-like receptor
family (Ly49/Klre1). Studies have shown interferon activated macrophages treated with
IL-13 have a reduced capacity to inhibit the growth of intracellular bacteria. A previous
transcriptional profiling study showed the increased expression of interferon activated genes
four days after infection in the lungs of mice infected with Type A FSC033 [13]. Moreover,
the killer cell lectin-like receptors have been shown to be vital for recognition and
activation/inhibition of natural killer cells [35,36]. Evidence that infection with F. tularensis
Schu4 decreased the expression of these receptors further highlights the immuno-evasive
activity of Francisella Schu4 compared to the less virulent F. tularensis LVS. Furthermore,
expression of the prostaglandin E1 receptor (Ptger1) confirms recent reports implicating
prostaglandin signaling as an important mechanism of Francisella manipulation of the host-
response to infection [46,33,42].
Our studies also indicate confirm previous studies and indicate that dissemination to
secondary sites of infection leading to multi-organ damage and failure are key contributing
factors to mortality from F. tularensis infection. We have also identified gene expression
patterns that may reflect immune responses to bacterial dissemination from the lung to
spleen tissues. These data may also be useful for facilitating the development of diagnostics
for monitoring treatment efficacy, the effectiveness of chemotherapeutic or vaccine
strategies. For example, gene expression correlates of host evasion during early infection
combined with gene expression signatures of dissemination provide a panel of genes that
can be used to assess disease progression and severity that can be used as checkpoints of
therapeutic efficacy. In addition, as high throughput RNA sequencing becomes more readily
available, biomarkers can be correlated to in vivo transcriptional data from the pathogen in
an attempt to decipher complex host-pathogen interactions. Importantly the expression of
markers that are associated with differences infection with LVS and Schu4 will be useful for
assessing immune response to immunotherapeutic drugs. These studies therefore provide a
foundation for continued research in this area that will ultimately provide unique
opportunities that can be exploited for the development of protective vaccines and effective
chemotherapeutics with enhanced efficacy and that prevent relapse of disease.
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Figure 1. Time-course of lung and spleen bacterial burden in mice infected with F. tularensis
LVS and Schu4
C57BL/6 mice (n = 4 per group) were inoculated i.n. with lethal doses of F. tularensis LVS
(104 CFU) or Schu4 (102 CFU), as described in Methods. Lung and spleen tissues were
collected 12, 24, 48 and 120 hours after infection and homogenized in TRiZol or PBS for
isolation or total RNA or CFU enumeration, error bars represent standard deviation of all 4
samples. (A) F. tularensis 16s rRNA detection in the lungs of mice infected with Schu4 and
LVS. (B) F. tularensis 16s rRNA detection in the spleens of mice infected with Schu4 and
LVS. Data show similar growth trends through 48 hours in the lung, whereas 120 hours post
infection Schu4 shows statistically significantly higher numbers in both the lung and spleen.
Data from each time point was subjected to students T-test, (*)=p<0.01, (**)=p<0.001.
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Figure 2. Time-course of lung and spleen pathology in mice infected with F. tularensis LVS and
Schu4
C57BL/6 mice (n = 4 per group) were inoculated i.n. with lethal doses of F. tularensis LVS
(104 CFU) or Schu4 (102 CFU), as described in Methods. Lung and spleen tissues were
collected 48 hours or 120 hours after infection and processed with hematoxylin and eosin
staining for histopathological examination. (A) Histology from the lung and spleen of
control (uninfected) mice. (B) Histology from the lung and spleen 48 hours post-infection
with Schu4 or LVS. (C) Histology from the lung and spleen 120 hours post-infection with
Schu4 or LVS. Pathological changes at 48 hours after infection were mild in both the lungs
and spleen and indistinguishable between F. tularensis LVS and Schu4 infected mice. At
120 hours after infection, more severe lesions were noted in the lungs and especially the
spleens of F. tularensis Schu4 infected mice, compared to LVS infected mice. Image
magnification was 40X for all images displayed.
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Figure 3. Functional enrichment of global transcriptional response data
C57BL/6 mice (n = 2 per group) were inoculated via aerosol with lethal doses of F.
tularensis LVS or Schu4 (104 CFU), as described in Methods. Total RNA from the lung and
spleen tissues was collected 12, 24, 48 and 120 hours post infection, converted to cDNA,
labeled and hybridized on full mouse genome microarrays. (A) Ontology analysis showing
select functional categories relevant to infection in the lung in response to infection with
Schu4 or LVS. (B) Ontology analysis showing select functional categories relevant to
infection in the spleen in response to infection with Schu4 or LVS. Genes with a p-value <
0.01 and differentially regulated > 1.5 fold were used for clustering and ontology analysis.
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